The Research of the Effect of Sevoflurane on Brain-protection of Cardiac Surgery in Infants.
Not Applicable
- Conditions
- Congenital Heart DiseaseInfant, Premature, Diseases
- Interventions
- Registration Number
- NCT03366597
- Lead Sponsor
- Jun Ma
- Brief Summary
To observe the effect of sevoflurane on the concentration of S100β and regional cerebral oxygen saturation in infants with congenital heart disease undergoing cardiac surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Clinical diagnosis of congenital heart disease
- Undergoing heart surgery with cardiopulmonary bypass
Exclusion Criteria
- Pulmonary arterial hypertension
- Sevoflurane allergy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Sevoflurane Sevoflurane Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
- Primary Outcome Measures
Name Time Method Concentration of S100β protein 5 minutes after tracheal intubation; immediately after cardiopulmonary bypass; immediately after operation; 12 hours, 24 hours postoperative The concentration of S100β protein was performed using the electrochemiluminescence immunoassay.(Blood samples from patients were drawn from central intravenous.)
- Secondary Outcome Measures
Name Time Method Level of regional cerebral oxygen saturation(rScO2) 5 minutes after tracheal intubation; immediately after cardiopulmonary bypass; immediately after operation; 12 hours, 24 hours postoperative The rScO2 was measured by using noninvasive near-infrared spectroscopy during cardiac surgery
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sevoflurane's neuroprotective effects in congenital heart disease infants during cardiac surgery?
How does sevoflurane compare to propofol in preserving cerebral oxygenation in infants with congenital heart disease undergoing cardiac surgery?
Which biomarkers like S100β and NSE are most predictive of neuroprotection outcomes in infant cardiac surgery using sevoflurane?
What are the potential adverse effects of sevoflurane on cerebral metabolism in premature infants with congenital heart disease during cardiac procedures?
How do volatile anesthetics like sevoflurane compare to intravenous agents in neuroprotection for cyanotic versus acyanotic congenital heart disease in infants?
Trial Locations
- Locations (1)
Beijing Anzhen Hospital
🇨🇳Beijing, Beijing, China
Beijing Anzhen Hospital🇨🇳Beijing, Beijing, ChinaJun Ma, MDContact010-64456329majun7689@163.com